SFTPA2 and COVID-19: Immunohistochemical staining of lung samples from COVID-19 patients has revealed dense accumulations of SP-A in the alveolar spaces; these abnormal accumulations are believed to hinder the distribution of exogenously administered surfactant preparations, thereby reducing treatment efficacy [28].